Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

Paper

Abstract

BACKGROUND: Preclinical studies suggest that bb2121, a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA), has potential for the treatment of multiple myeloma. METHODS: CAR+ T cells in the expansion phase. Patients had received at least three previous lines of therapy, including a proteasome inhibitor and an immunomodulatory agent, or were refractory to both drug classes. The primary end point was safety. RESULTS: nucleated cells). CAR T-cell expansion was associated with responses, and CAR T cells persisted up to 1 year after the infusion. CONCLUSIONS: We report the initial toxicity profile of a BCMA-directed cellular immunotherapy for patients with relapsed or refractory multiple myeloma. Antitumor activity was documented. (Funded by Bluebird Bio and Celgene; CRB-401 ClinicalTrials.gov number, NCT02658929.).

Analysis

Paper intelligence

Summary

This study reports the initial safety and antitumor activity of bb2121, a BCMA-targeted CAR T-cell therapy, in patients with relapsed or refractory multiple myeloma.

Key findings

bb2121 demonstrated antitumor activity in patients with relapsed or refractory multiple myeloma.
CAR T-cell expansion was associated with responses.
CAR T cells persisted up to 1 year post-infusion.
The initial toxicity profile was documented.

Methods

CAR+ T cells were administered to patients.
Patients had received at least three previous lines of therapy or were refractory to proteasome inhibitors and immunomodulatory agents.
Safety was the primary end point.

Limitations

The study reports initial toxicity profile.
The abstract does not detail specific adverse events or response rates beyond association with expansion.

Applications

Treatment of relapsed or refractory multiple myeloma.

Confidence100%

Discovery

Related papers

2027PubMed

Nucleofection-Based CRISPR/Cas Delivery in Human T Cells for Immunotherapy Applications.

Ortiz-Bueno M; Millán-López A; Labun K; Benabdellah K

Jan 1, 2027Methods in molecular biology (Clifton, N.J.)

2027PubMed

Harnessing necroptosis via RIPK1 degradation to potentiate radio-immunotherapy in cervical cancer.

Wu T; Lv B; Wang H; He G; Fu Y; Ji X; Zeng Y; Ni D; Qiu J; Hua K

Jan 1, 2027Bioactive materials

2026arXiv

Combining standard chemoradiotherapy with CAR-T cell therapy in malignant gliomas: Insights from an impulsive mathematical framework and virtual trials

Dmitry Sinelshchikov; Nikols Amaru Mora Millán; Miguel Perales-Patón; Juan Belmonte-Beitia; Matteo Italia

Sep 30, 2026

2026Crossref1 citations

From monolayer to organoids and multi-organ microphysiological systems: advancing regenerative medicine and precision therapies

Mahmood S. Choudhery; Ahmad Niaz; Taqdees Arif; Ruhma Mahmood

Jul 2, 2026Stem Cell Research & Therapy

2026Crossref0 citations

CAR-Mix cell therapies to treat solid tumors by providing synergistic interaction between engineered macrophages and polyclonal T cells.

Xudong Wang; Jin Zhang

Jun 1, 2026Journal of Clinical Oncology

2026Crossref0 citations

Intraosseous therapy: harnessing the potential of tissue regeneration and repair

Mikhail Yu. Artamonov; Inessa A. Minenko

May 8, 2026Frontiers in Medicine

Source record

Publication metadata

Authors: Noopur Raje; Jesús G. Berdeja; Yi Lin; David S. Siegel; Sundar Jagannath; Deepu Madduri; Michaela Liedtke; Jacalyn Rosenblatt; Marcela V. Maus; Ashley Turka; Lyh-Ping Lam; Richard A. Morgan; Kevin M. Friedman; Monica Massaro; Julie Wang; Greg Russotti; Zhihong Yang; Timothy Campbell; Kristen Hege; Fabio Petrocca; M. Travis Quigley; Nikhil C. Munshi; James N. Kochenderfer
Published: May 1, 2019
Journal or venue: New England Journal of Medicine
DOI: 10.1056/nejmoa1817226
Paper type: journal article
Source: Openalex

DOI OpenAlex